694 related articles for article (PubMed ID: 26921806)
1. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
[TBL] [Abstract][Full Text] [Related]
2. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
[TBL] [Abstract][Full Text] [Related]
3. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
Yamamoto A; Okada AA; Kano M; Koizumi H; Saito M; Maruko I; Sekiryu T; Iida T
Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
[TBL] [Abstract][Full Text] [Related]
4. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
[TBL] [Abstract][Full Text] [Related]
5. ANGIOGRAPHIC FINDINGS OF RANIBIZUMAB-RESISTANT POLYPOIDAL CHOROIDAL VASCULOPATHY AFTER SWITCHING TO A TREAT-AND-EXTEND REGIMEN WITH INTRAVITREAL AFLIBERCEPT.
Azuma K; Obata R; Nomura Y; Tan X; Takahashi H; Yanagi Y
Retina; 2016 Nov; 36(11):2158-2165. PubMed ID: 27258669
[TBL] [Abstract][Full Text] [Related]
6. Short-term efficacy of intravitreal aflibercept for patients with treatment-naïve polypoidal choroidal vasculopathy.
Ijiri S; Sugiyama K
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):351-7. PubMed ID: 25023147
[TBL] [Abstract][Full Text] [Related]
7. AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing.
Inoue M; Yamane S; Taoka R; Arakawa A; Kadonosono K
Retina; 2016 Aug; 36(8):1527-34. PubMed ID: 26710307
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
Komuku Y; Iwahashi C; Gomi F
Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
[TBL] [Abstract][Full Text] [Related]
9. ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Hara C; Sawa M; Sayanagi K; Nishida K
Retina; 2016 Jan; 36(1):37-45. PubMed ID: 26383709
[TBL] [Abstract][Full Text] [Related]
10. INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION.
Cho HJ; Hwang HJ; Kim HS; Han JI; Lee DW; Kim JW
Retina; 2018 Nov; 38(11):2150-2158. PubMed ID: 28984737
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with polyp regression after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.
Cho HJ; Han SY; Kim HS; Lee TG; Kim JW
Jpn J Ophthalmol; 2015 Jan; 59(1):29-35. PubMed ID: 25373450
[TBL] [Abstract][Full Text] [Related]
13. Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
Sakai T; Okano K; Kohno H; Tsuneoka H
Acta Ophthalmol; 2016 Dec; 94(8):e765-e771. PubMed ID: 27237048
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Br J Ophthalmol; 2015 Sep; 99(9):1284-8. PubMed ID: 25777816
[TBL] [Abstract][Full Text] [Related]
15. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability.
Nomura Y; Yanagi Y
Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109
[TBL] [Abstract][Full Text] [Related]
17. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
Kang HM; Koh HJ; Lee CS; Lee SC
Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
[TBL] [Abstract][Full Text] [Related]
18. Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy.
Cho HJ; Kim K; Lim SH; Kang DH; Kim JW
Br J Ophthalmol; 2020 Oct; 104(10):1443-1447. PubMed ID: 31896542
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.
Lee JH; Lee WK
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):645-51. PubMed ID: 26138657
[TBL] [Abstract][Full Text] [Related]
20. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
Saito M; Kano M; Itagaki K; Oguchi Y; Sekiryu T
Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
